# A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Source: https://onco.cc/trials/nct04988555/  
OnCo record `nct04988555` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Venetoclax, Gilteritinib, Azacitidine in multiple myeloma, run by Sumitomo Pharma America, Inc., now recruiting.

## Summary

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) is a phase 1/2 interventional study registered as NCT04988555 by Sumitomo Pharma America, Inc., with 606 participants planned, started 2022-02-28 and due to reach its primary completion in 2027-06-30. Interventions recorded: Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA). Conditions listed: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04988555
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)
- Sponsor: Sumitomo Pharma America, Inc.
- Enrolled: 606

## Sources

- ClinicalTrials.gov NCT04988555: https://clinicaltrials.gov/study/NCT04988555

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Sumitomo Pharma (Myovant)](https://onco.cc/companies/sumitomo-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04988555.json